KR101773506B1 - Ｍｕｃ1 항체 - Google Patents

Ｍｕｃ1 항체 Download PDF

Info

Publication number
KR101773506B1
KR101773506B1 KR1020127005121A KR20127005121A KR101773506B1 KR 101773506 B1 KR101773506 B1 KR 101773506B1 KR 1020127005121 A KR1020127005121 A KR 1020127005121A KR 20127005121 A KR20127005121 A KR 20127005121A KR 101773506 B1 KR101773506 B1 KR 101773506B1
Authority
KR
South Korea
Prior art keywords
ser
antibody
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127005121A
Other languages
English (en)
Korean (ko)
Other versions
KR20120051724A (ko
Inventor
슈테펜 골렛츠
안트제 다니엘치크
레나트 슈탄
우베 카르스텐
Original Assignee
글리코토페 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글리코토페 게엠베하 filed Critical 글리코토페 게엠베하
Publication of KR20120051724A publication Critical patent/KR20120051724A/ko
Application granted granted Critical
Publication of KR101773506B1 publication Critical patent/KR101773506B1/ko
Assigned to 다이이찌 산쿄 가부시키가이샤 reassignment 다이이찌 산쿄 가부시키가이샤 권리의 전부이전등록 Assignors: 글리코토페 게엠베하
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020127005121A 2009-07-31 2010-07-30 Ｍｕｃ1 항체 Active KR101773506B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
US61/230,211 2009-07-31
EP09009942.5 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies
PCT/EP2010/004663 WO2011012309A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Publications (2)

Publication Number Publication Date
KR20120051724A KR20120051724A (ko) 2012-05-22
KR101773506B1 true KR101773506B1 (ko) 2017-08-31

Family

ID=41460131

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127005121A Active KR101773506B1 (ko) 2009-07-31 2010-07-30 Ｍｕｃ1 항체

Country Status (17)

Country Link
US (1) US9217038B2 (https=)
EP (3) EP2281844A1 (https=)
JP (2) JP5922018B2 (https=)
KR (1) KR101773506B1 (https=)
CN (1) CN102574926B (https=)
AR (1) AR077334A1 (https=)
AU (1) AU2010278302B2 (https=)
BR (1) BR112012002226A2 (https=)
CA (1) CA2768888C (https=)
CU (1) CU23972B1 (https=)
EA (1) EA029954B1 (https=)
IL (1) IL217827A (https=)
MX (1) MX2012000874A (https=)
NZ (1) NZ597563A (https=)
SG (2) SG177527A1 (https=)
WO (1) WO2011012309A1 (https=)
ZA (1) ZA201200166B (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2073842T1 (sl) 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
WO2012020065A1 (en) 2010-08-10 2012-02-16 Glycotope Gmbh Fab-glycosylated antibodies
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
CN105008550B (zh) 2013-03-01 2018-03-30 学校法人埼玉医科大学 包含对muc4基因多态性进行检测的步骤的、判定抗癌剂疗法的副作用的发生风险的方法
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
RU2016133593A (ru) * 2014-02-06 2018-03-07 Медисинал Кемистри Фармасьютикал Ко., Лтд. Антитело против гликопептида муцина 4 (muc4) и его применение
AU2015254257B2 (en) * 2014-04-28 2021-02-25 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof
WO2016026143A1 (en) 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
CN112105384B (zh) * 2017-01-18 2024-08-23 苏州启航纳米药物有限公司 癌糖肽的单克隆和人源化抗体
CA3050039A1 (en) * 2017-01-27 2018-08-02 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
CA3055433A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
CN111315776A (zh) * 2017-03-29 2020-06-19 葛莱高托普有限公司 Pd-l1和ta-muc1抗体
AU2018241781A1 (en) * 2017-03-29 2019-07-18 Glycotope Gmbh Multispecific antibody constructs binding to MUC1 and CD3
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
MX2020004220A (es) * 2017-10-24 2020-10-05 Go Therapeutics Inc Anticuerpos anti-glico-muc1 y sus usos.
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物
MX2020012351A (es) * 2018-05-17 2021-01-29 Astellas Pharma Inc Complejo que tiene fragmento fab de anticuerpo anti-muc1 de humano, enlazador peptido y/o ligando.
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
JP7541930B2 (ja) * 2018-06-29 2024-08-29 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用
CA3115747A1 (en) 2018-10-10 2020-04-16 Astellas Pharma Inc. Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
TWI841715B (zh) 2019-03-27 2024-05-11 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
AU2022420709A1 (en) * 2021-12-21 2024-08-01 Merus B.V. Binding domains against cancer-associated muc1
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
EP0636029B1 (en) 1992-04-13 2000-11-08 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) * 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
SI1530628T1 (sl) 2002-08-16 2011-02-28 Glycotope Gmbh Postopek za proizvodnjo s temperaturo induciranih lizatov tumorskih celic za uporabo kot imunogenske spojine
ES2425475T3 (es) 2003-08-18 2013-10-15 Glycotope Gmbh Líneas de células tumorales NM-F9 (DSM ACC2606) y NM-D4 (DSM ACC2605), usos de las mismas
EP1725673A1 (en) 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies

Also Published As

Publication number Publication date
EP2281844A1 (en) 2011-02-09
SG10201404019XA (en) 2014-09-26
EA201270207A1 (ru) 2012-07-30
CN102574926A (zh) 2012-07-11
KR20120051724A (ko) 2012-05-22
AR077334A1 (es) 2011-08-17
BR112012002226A2 (pt) 2016-11-08
NZ597563A (en) 2013-08-30
MX2012000874A (es) 2012-02-01
CA2768888A1 (en) 2011-02-03
IL217827A0 (en) 2012-03-29
AU2010278302A1 (en) 2012-02-09
US9217038B2 (en) 2015-12-22
JP2016041771A (ja) 2016-03-31
ZA201200166B (en) 2013-03-27
CN102574926B (zh) 2014-10-15
IL217827A (en) 2017-05-29
CA2768888C (en) 2019-02-26
EP2459595A1 (en) 2012-06-06
JP5922018B2 (ja) 2016-05-24
EP3421497A1 (en) 2019-01-02
JP2013500703A (ja) 2013-01-10
SG177527A1 (en) 2012-02-28
JP6272916B2 (ja) 2018-01-31
CU23972B1 (es) 2013-12-27
EA029954B1 (ru) 2018-06-29
CU20120019A7 (es) 2012-06-21
US20120128676A1 (en) 2012-05-24
WO2011012309A1 (en) 2011-02-03
AU2010278302B2 (en) 2014-12-18
WO2011012309A8 (en) 2011-04-07

Similar Documents

Publication Publication Date Title
KR101773506B1 (ko) Ｍｕｃ1 항체
KR101782487B1 (ko) 신규 항-메소텔린 항체 및 이를 포함하는 조성물
JP5568478B2 (ja) 癌細胞で発現するｃｄ−４３およびｃｅａの炭水化物含有エピトープを認識する抗体およびそれを使用する方法
EP3130607B1 (en) Muc1* antibodies
TW202525859A (zh) 全人源的抗ｂ細胞成熟抗原（ｂｃｍａ）單鏈抗體及其應用
JP2021524740A (ja) 抗ｍｕｃ１抗体
EP3981793A1 (en) Ceacam5-resistant monoclonal antibody and preparation method thereof and use thereof
EP4289862A1 (en) Anti-human b7-h3 antibody and application thereof
JPWO2015053381A1 (ja) 抗ポドプラニン抗体
JP7410051B2 (ja) 細胞内への鉄の取り込み阻害剤
WO2022075439A1 (ja) 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
WO2023027164A1 (ja) Ｒｏｓ（活性酸素種）産生増強剤
JP7622926B2 (ja) 癌性腹膜炎の治療薬
JP6847434B2 (ja) 抗ポドプラニン抗体
EP4512423A1 (en) Therapeutic agent for nk cell tumor
EP4703383A1 (en) Prolactin receptor antibody and use thereof
HK40122549A (en) Therapeutic agent for nk cell tumor
HK40068402A (en) Ceacam5-resistant monoclonal antibody and preparation method thereof and use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150730

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20161220

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20170622

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170825

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170828

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200818

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210817

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220817

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20230816

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20240813

Start annual number: 8

End annual number: 8